ICU-acquired weakness: critical illness polyneuropathy and myopathy · ICU Topics

Cinematic ICU scene of a long-stay ICU patient with global muscle wasting, an MRC sum-score chart at the bedside, an early-mobility physiotherapy session, an electrophysiology trace, clinical-blue lighting, medical educational, no faces, no text — FigureICU-acquired weakness — the muscle and nerve that critical illness destroys, in a quarter to a half of the long-stay patients. Critical illness polyneuropathy is axonal and sensorimotor; critical illness myopathy is the fibre atrophy; combined disease is the commonest. Risk: sepsis, immobilisation, corticosteroids, neuromuscular blockade, hyperglycaemia. Prevent it — light sedation, early mobilisation, glycaemic control, spare the steroids and the blockers. Rehabilitate.

CIP vs CIM vs CINM

Feature	CIP (Polyneuropathy)	CIM (Myopathy)	CINM (Combined)
Site	Peripheral NERVE (axonal)	MUSCLE (myopathy)	Both nerve + muscle
Pathology	Distal axonal degeneration	Myofibre atrophy, myosin loss	Both
Weakness	Distal > proximal (sensorimotor)	Proximal > distal (or generalised)	Generalised
Sensation	Reduced (sensory neuropathy)	Normal	May be reduced
NCS	Reduced CMAP + SNAP (axonal)	Reduced CMAP, normal SNAP	Reduced CMAP, ± SNAP
EMG	Denervation (fibrillation, positive sharp waves)	Myopathic (small motor units, early recruitment)	Mixed
Biopsy	Nerve: axonal loss	Muscle: atrophy (myosin loss), necrosis	Both
Most common	~30%	~20%	~50% (most common)
Recovery	Slow (months-years)	Faster (weeks-months)	Variable

[1]

Diagnosis and management of ICU-acquired weakness

SUSPECT ICUAW — difficulty weaning from ventilator, flaccid limbs, unable to lift arms/legs off bed, in patient with prolonged ICU stay (>1 week), sepsis, steroids, NMBA exposure
EXCLUDE other causes — (a) Residual neuromuscular blockade (train-of-four, reversal). (b) Electrolyte disturbance (K+, Mg2+, Ca2+, phosphate). (c) Spinal cord injury. (d) Guillain-Barré. (e) Myasthenia gravis. (f) Steroid myopathy. (g) Cachexia/malnutrition
CLINICAL DIAGNOSIS — MRC sum score: assess 6 muscle groups (arm flexion, arm abduction, wrist extension, leg flexion, leg extension, dorsiflexion), bilateral, 0-5 each. Score <48/60 = ICUAW. Requires: awake, cooperative, able to follow commands
ELECTROPHYSIOLOGY (if available) — NCS (nerve conduction study): reduced CMAP + SNAP (axonal). EMG: denervation (CIP) or myopathic (CIM). Helps distinguish CIP vs CIM
PREVENTION (most effective strategy): (a) Minimise sedation (dexmedetomidine, SAT). (b) Early mobilisation (day 1-2 — ABCDE trial). (c) Glycaemic control (6-10 mmol/L — NICE-SUGAR). (d) Avoid/minimise corticosteroids + NMBA. (e) Adequate nutrition (protein 1.2-1.5 g/kg/day). (f) Avoid prolonged bed rest
TREATMENT — supportive: (a) Rehabilitation (physiotherapy, occupational therapy). (b) Early mobilisation (progressive — passive → active → walking). (c) Nutritional support (adequate protein). (d) Manage expectations (recovery is SLOW — months-years)
RECOVERY — monitor over weeks-months. Most improve, but may take 1-5 years. Some never fully recover (permanent disability). Predictors of poor recovery: severe weakness, prolonged ICU stay, older age

[1]

SAQ — Difficulty weaning after prolonged septic ICU stay: diagnosing CIP

10 minutes · 10 marks

A 64-year-old man is day 16 of a prolonged ICU admission for pneumococcal pneumonia complicated by septic shock and ARDS. He has received 5 days of cisatracurium infusion and a 7-day course of hydrocortisone 200 mg/day for refractory vasopressor-dependent shock. Sedation has now been lightened and he is awake and cooperative, but he has failed three spontaneous breathing trials and is unable to lift his arms or legs off the bed. He has flaccid, areflexic limbs with reduced sensation distally. He asks why he cannot move.

[1]

SAQ — Preventing critical illness myopathy in a high-risk ARDS patient

10 minutes · 10 marks

A 52-year-old woman with severe ARDS from influenza pneumonitis (PaO₂/FiO₂ 70) has been ventilated for 48 hours on volume-control ventilation with a PEEP of 14, FiO₂ 0.8. She is on propofol and fentanyl infusions, has received 48 hours of cisatracurium for profound hypoxaemia per the ACURASYS protocol, and was started on dexamethasone 20 mg daily. Blood glucose is 14 mmol/L. The consultant asks you to outline a strategy to prevent ICU-acquired weakness, particularly critical illness myopathy (CIM).

[1]

Clinical pearls

Pathophysiology of ICUAW: CIP (axonal sensorimotor polyneuropathy) versus CIM (thick-filament myopathy) versus combined CINM, driven by sepsis, immobilisation, steroids, NMBA, and hyperglycaemia — FigureCIP is axonal sensorimotor; CIM is myosin-loss myopathy; most patients have combined disease. Sepsis, immobility, steroids, NMBA, and hyperglycaemia are the reversible drivers.

ICUAW prevention and rehab: light sedation, early mobilisation, glycaemic control 6–10 mmol/L, minimise steroids/NMBA, structured physiotherapy — FigurePrevention beats cure: light sedation, early mobility, moderate glycaemic control, spare steroids and neuromuscular blockade, then prolonged rehabilitation.

[1]

High-yield ICUAW/CIP/CIM points for CICM/FFICM exam

ICUAW affects 25-50% of long-stay ICU patients. Higher in: sepsis (50-70%), ARDS (60-80%), prolonged ventilation (>7 days), multi-organ failure. VERY COMMON — any ICU patient with >1 week stay should be assessed. Major contributor to post-intensive care syndrome (PICS — physical domain).[1] }
MRC sum score <48/60 = ICUAW. Medical Research Council scale: 6 muscle groups × 2 sides × 0-5 scale = maximum 60. Score <48 = ICUAW. Requires: AWAKE, cooperative (follows commands). Can't assess in: sedated, paralysed, comatose patients. LIMITATION: subjective (inter-observer variability), needs cooperation. BEST bedside tool available.[2] }
Sepsis is the STRONGEST risk factor. Sepsis → systemic inflammation → microvascular dysfunction → nerve/muscle ischaemia + catabolism → axonal degeneration + myofibre atrophy. Other risk factors: multi-organ failure, prolonged immobilisation, corticosteroids, neuromuscular blockade, hyperglycaemia, female sex, age >60.[1] }
Muscle wasting occurs RAPIDLY — 2% per day in first week. Puthucheary (JAMA 2013): quadriceps muscle mass decreased by ~12.5% in first week of critical illness (by ultrasound). Rate: ~2% per day. Worse with: sepsis, multi-organ failure. Mechanism: protein degradation (ubiquitin-proteasome, autophagy) exceeds protein synthesis (anabolic resistance).[3] }
Early mobilisation REDUCES ICUAW (ABCDE trial). Schweickert (Lancet 2009): early mobilisation + interrupting sedation vs usual care. Result: MORE days alive without delirium or coma, MORE independent at discharge (59% vs 35%), trend to shorter ventilation. Get patients OUT OF BED from day 1-2 (even passive if ventilated).[4] }
Glycaemic control reduces ICUAW (NICE-SUGAR controversy). Original Van den Berghe (2001): intensive insulin (4.4-6.1 mmol/L) reduced CIP from 52% to 29%. BUT NICE-SUGAR (2009): intensive control → MORE hypoglycaemia, no mortality benefit. Current: moderate control (6-10 mmol/L) — avoid both hyperglycaemia (worsens ICUAW) and hypoglycaemia (harmful).[5] }
Avoid corticosteroids and NMBA if possible. STEROIDS: high-dose → myopathy (especially with simultaneous NMBA — 'critical illness myopathy'). But: sometimes needed (ARDS — DExa-ARDS, CIRCI — septic shock). Balance: use when indicated, minimise dose/duration. NMBA (cisatracurium): ACURASYS — 48h improved ARDS outcomes. ROSE — no benefit. If used: minimise duration, avoid simultaneous high-dose steroids.[1] }
Difficulty weaning from ventilator — consider ICUAW. Weak respiratory muscles (diaphragm, intercostals) → cannot generate negative inspiratory force → weaning failure. Assess: NIF (negative inspiratory force < -30 cmH2O = weak), vital capacity. Diagnosis: ICUAW affecting respiratory muscles (CIP/CIM). Management: progressive ventilator weaning, respiratory muscle training, patience (recovery takes weeks-months).[1] }
CIP is AXONAL (not demyelinating). Distinguishes from: Guillain-Barré (demyelinating — prolonged distal latencies, conduction block). CIP: REDUCED CMAP + SNAP amplitudes (axonal loss) with NORMAL conduction velocity (not slowed — no demyelination). Nerve biopsy: axonal degeneration (Wallerian — distal nerves worst affected). Recovery: axonal REGROWTH (1 mm/day — SLOW — months to years).[1] }
CIM is characterised by MYOSIN LOSS (thick filament loss). Muscle biopsy: preferential loss of myosin (thick myofilament) → muscle weakness (myosin is the force-generating protein). Also: type II fibre atrophy (fast-twitch — less used in bed rest), necrosis (in severe cases). Electrophysiology: reduced CMAP (muscle can't generate force) but NORMAL SNAP (nerve intact — distinguishes from CIP). Recovery: faster than CIP (myofibre regeneration — weeks-months).[1] }
Nutrition is important but cannot prevent ICUAW alone. Adequate protein (1.2-1.5 g/kg/day): supports muscle protein synthesis. BUT: critical illness → 'anabolic resistance' (muscle doesn't respond normally to nutrition/insulin → protein breakdown continues despite feeding). So: nutrition HELPS (slows wasting) but CANNOT PREVENT ICUAW alone (inflammation, immobility, catabolism dominate). Newer: protein supplementation, β-hydroxy β-methylbutyrate (HMB), exercise — combination may help.[3] }
Distinguish ICUAW from residual neuromuscular blockade. NMBA (cisatracurium, rocuronium) → paralysis. If not fully reversed: persistent weakness (looks like ICUAW). Check: train-of-four (TOF — 4 twitches = full recovery). Reversal: neostigmine/sugammadex (for rocuronium). ICUAW: persistent weakness AFTER full NMBA reversal. Time course: NMBA wears off in hours; ICUAW persists for weeks-months.[1] }
Long-term outcomes — recovery is SLOW and may be incomplete. Needham (AJRCCM 2019): ICUAW survivors at 1 year: 30-50% still have weakness. Physical function: many never return to pre-ICU (especially elderly). Predictors of poor recovery: severe weakness (MRC <36), prolonged ICU stay, older age, pre-existing frailty. Some: permanent disability (wheelchair, walking aid). Quality of life: reduced (especially physical domain).[6] }
PICS — ICUAW is the PHYSICAL domain. Post-Intensive Care Syndrome: (1) COGNITIVE (40% impaired). (2) PHYSICAL (ICUAW — 30-50% with weakness). (3) PSYCHOLOGICAL (PTSD 20%, depression 30%). All three contribute to long-term disability after ICU. ICUAW is the most visible (physical — difficulty walking, self-care). Prevention (ABCDEF bundle, early mobility) + rehabilitation are KEY.[6] }

Red flags

Prognosis

ABCDE trial (Schweickert 2009, Lancet) — early mobilisation for ICUAW prevention

RCT: 104 ICU patients on mechanical ventilation. Early mobilisation + sedation interruption vs usual care.

Primary outcome (days alive without delirium or coma): early 2.9 vs usual 0 (more days without delirium)
Independent at discharge (able to perform ADLs): early 59% vs usual 35% (p=0.02 — SIGNIFICANT)
ICUAW at discharge (MRC <48): early 30% vs usual 60% (trend — not significant, but clinically important)
Ventilation days: similar (no difference)
CONCLUSION: Early mobilisation (with sedation interruption) IMPROVES functional outcomes and reduces ICUAW. Get patients OUT OF BED from day 1-2 (even if ventilated). [1]

Puthucheary (JAMA 2013): quadriceps mass decreased ~12.5% in first week (2%/day). Worse with sepsis. Van den Berghe (2001): intensive insulin reduced CIP from 52% to 29% (but NICE-SUGAR — moderate control now recommended). Recovery: 1-year: 30-50% still weak. Some never fully recover (permanent disability).

[1]

Electrophysiological discrimination — CIP vs CIM vs CINM

Electrophysiological discrimination: nerve conduction, direct muscle stimulation, and needle EMG

Test	CIP (polyneuropathy)	CIM (myopathy)	CINM (combined)
Pathology site	Distal sensory + motor AXON degeneration	MUSCLE fibre (myosin loss, atrophy)	Both nerve + muscle
Nerve CMAP (compound muscle action potential — nerve stimulation)	REDUCED (axonal loss — fewer axons reaching muscle)	REDUCED (muscle can't generate force)	REDUCED
SNAP (sensory nerve action potential)	REDUCED (sensory axonal loss)	NORMAL (sensory nerve intact)	REDUCED (±normal)
Direct muscle stimulation CMAP (stimulate muscle directly — bypasses nerve)	NORMAL (muscle intact — nerve is the problem)	REDUCED (muscle itself is diseased)	REDUCED
KEY: Nerve CMAP vs direct muscle CMAP	Nerve CMAP < direct muscle CMAP (nerve is problem)	Nerve CMAP ≈ direct muscle CMAP (both low — muscle is problem)	Both reduced
Conduction velocity	NORMAL or mildly reduced (axonal — NOT demyelinating)	NORMAL	NORMAL or mildly reduced
Distal latency	Normal (no demyelination)	Normal	Normal
Needle EMG	Denervation potentials (fibrillation, positive sharp waves) — neurogenic	Myopathic units (small, short-duration polyphasic, EARLY recruitment)	MIXED (denervation + myopathic units)
Repetitive stimulation (to exclude MG)	Normal decrement	Normal decrement	Normal decrement
Phrenic nerve / diaphragm EMG	Abnormal if respiratory involvement	May be abnormal	May be abnormal
Interpretation tip	Reduced CMAP + REDUCED SNAP = AXONAL NEUROPATHY (CIP)	Reduced CMAP + NORMAL SNAP + reduced direct muscle CMAP = MYOPATHY (CIM)	Reduced CMAP + reduced SNAP + reduced direct muscle CMAP = COMBINED (CINM)

[1]

Electrophysiology deep dive — how to actually distinguish CIP, CIM and CINM at the bedside

Nerve CMAP and SNAP are the two key nerve-conduction measurements. CMAP = motor response (stimulate nerve, record from muscle). SNAP = sensory response (stimulate and record from sensory nerve). In CIP (axonal neuropathy) BOTH CMAP and SNAP are reduced (because axons are lost — fewer nerve fibres conduct). In CIM (myopathy) CMAP is reduced (muscle can't generate force) but SNAP is NORMAL (the sensory nerve is intact). So the SINGLE most discriminating test between CIP and CIM is the SNAP: reduced = CIP, normal = CIM.[11] }
Direct muscle stimulation (DMS) is the gold-standard discriminator. Problem: a reduced nerve CMAP could be from nerve damage (CIP) OR muscle damage (CIM) — both reduce CMAP. Solution: stimulate the MUSCLE directly (bypass the nerve entirely). If DMS-CMAP is NORMAL → muscle is fine → problem is in the NERVE (CIP). If DMS-CMAP is REDUCED → muscle itself is diseased (CIM). If BOTH nerve CMAP and DMS-CMAP are reduced → combined nerve + muscle disease (CINM). DMS is technically harder (requires expertise) but is the definitive discriminator when NCS is ambiguous.[12] }
Needle EMG distinguishes neurogenic from myopathic patterns. CIP (denervated muscle): FIBRILLATION potentials + POSITIVE SHARP WAVES at rest (denervation), and on voluntary contraction: large-amplitude, long-duration, polyphasic motor units with REDUCED recruitment (fewer motor units survive). CIM (myopathic): small-amplitude, short-duration polyphasic motor units with EARLY (excessive) recruitment (lots of motor units fire to generate weak force — muscle is weak per unit). MIXED pattern = CINM. LIMITATION: requires patient cooperation (voluntary activation) — hard in sedated ICU patients.[11] }
CIP is AXONAL — not demyelinating. This is a crucial discriminator from Guillain-Barré. CIP: reduced amplitudes (axonal loss) with NORMAL conduction velocity and NORMAL distal latency (no demyelination). GBS: DEMYELINATING → slowed conduction velocity, prolonged distal latency, conduction block, prolonged F-waves. So if you see SLOWED conduction velocity or conduction block, think GBS (or CIDP), NOT CIP. CIP never shows demyelinating features.[1] }
Timing of electrophysiology matters. CIP/CIM take DAYS to develop — electrophysiology is NORMAL in the first few days. Earliest changes: reduced CMAP (days 3-7). SNAP reduction, fibrillation on EMG: 1-3 weeks (Wallerian degeneration takes time). So early weakness (day 1-2) is more likely residual NMBA, electrolytes, or pre-existing disease. ICUAW electrophysiology is best assessed after day 7 (when changes are established).[11] }

Risk factors for ICU-acquired weakness — modifiable vs non-modifiable

Risk factor	Mechanism	Relative risk	Modifiable?
Sepsis / systemic inflammation (STRONGEST)	Microvascular dysfunction, cytokine-mediated catabolism, mitochondrial dysfunction in nerve + muscle	RR 2-4	Partly (early source control, antibiotics)
Multi-organ failure	Cumulative catabolism, hypoxia, oxidative stress	RR 3-5	Partly
Corticosteroids (high-dose, prolonged)	Steroid myopathy — preferential type IIb fibre atrophy, myosin loss; synergistic with NMBA	RR 2-3	YES — minimise dose/duration
Neuromuscular blocking agents (NMBA)	Prolonged blockade, upregulation of acetylcholine receptors, synergistic myopathy with steroids	RR 1.5-2	YES — minimise duration, monitor TOF
Hyperglycaemia	Cellular damage via glycation, oxidative stress, impaired axonal transport	RR 2	YES — glycaemic control (6-10 mmol/L)
Immobilisation / bed rest	Disuse atrophy (type I fibre), anabolic resistance, insulin resistance	RR 1.5-2	YES — early mobilisation
Mechanical ventilation (prolonged)	Diaphragm dysfunction (VIDD — ventilator-induced diaphragm dysfunction), bed rest	RR 2	Partly — minimise ventilation days
ARDS / hypoxaemia	Hypoxic nerve/muscle damage, high ventilator pressures, inflammation	RR 3-4	Partly — lung-protective ventilation
Age > 60	Reduced baseline muscle mass (sarcopenia), impaired regeneration	RR 1.5-2	No
Female sex	Lower baseline muscle mass	RR 1.3-1.5	No
Alcohol misuse / pre-existing neuropathy	Additive nerve damage	RR 2	Partly
Renal failure (AKI/dialysis)	Uraemic neuropathy, electrolyte disturbance, volume shifts	RR 2	Partly
Severe illness (APACHE II high)	Surrogate for severity/inflammation	RR 2-3	No
Vasopressors (catecholamines)	Peripheral vasoconstriction → nerve/muscle ischaemia; surrogate for severity	RR 1.5-2	Partly

[1]

Risk factor pearls — what actually causes ICUAW

Sepsis is the STRONGEST and most consistently identified risk factor. Up to 70% of septic shock patients develop ICUAW. Mechanism: sepsis → systemic inflammation (TNF-α, IL-1, IL-6) → (1) microvascular dysfunction → nerve/muscle ischaemia, (2) mitochondrial dysfunction → energy failure, (3) upregulation of ubiquitin-proteasome + autophagy pathways → protein degradation, (4) impaired protein synthesis (anabolic resistance). The degree of muscle wasting correlates with inflammatory markers (CRP, IL-6).[1] }
Steroids + NMBA together = HIGHEST risk of critical illness myopathy. The combination of high-dose corticosteroids AND neuromuscular blocking agents (e.g., for severe ARDS) causes a SEVERE myopathy with preferential myosin (thick filament) loss — the classic 'critical illness myopathy' described in asthmatics on ventilators with steroids and NMBAs. Mechanism: steroids upregulate muscle proteolysis; NMBAs reduce muscle activation (disuse) and may have direct myotoxicity. LESSON: if you MUST use both (e.g., severe ARDS with difficult oxygenation), minimise duration and depth of blockade.[1] }
Hyperglycaemia independently increases ICUAW — glycaemic control helps. Hyperglycaemia → glycation of proteins, oxidative stress, impaired axonal transport, neuronal damage. Van den Berghe (2001): intensive insulin (4.4-6.1 mmol/L) reduced CIP electrophysiological abnormalities from 52% to 29%. BUT NICE-SUGAR (2009): intensive control → more hypoglycaemia, no mortality benefit. Current consensus (PADIS, SCCM): moderate control — target 6-10 mmol/L (avoid hyperglycaemia AND hypoglycaemia).[8] }
Immobilisation causes disuse atrophy — even in healthy people. Healthy older adults lose 0.5-1% muscle mass per DAY of bed rest (much faster than ICUAW rate in young healthy). In ICU (with inflammation, catabolism): up to 2-3% per day. Immobilisation → (1) mechanical unloading → anabolic resistance, (2) reduced neural activation → denervation-like changes, (3) insulin resistance. SOLUTION: get patients moving — even passive range of motion, sitting on edge of bed, standing.[3] }
Ventilator-induced diaphragm dysfunction (VIDD) is a form of ICUAW affecting respiratory muscles. Mechanical ventilation → diaphragm inactivity → rapid atrophy (diaphragm loses strength within 18 hours of controlled ventilation). Mechanism: oxidative stress, proteolysis, contractile remodelling. VIDD contributes to weaning failure. PREVENT: minimise controlled ventilation (use assist/pressure support modes, spontaneous breathing trials), minimise ventilation DAYS.[1] }

Prevention — the ABCDEF bundle

ABCDEF bundle for ICUAW prevention (SCCM/PADIS)

Element	Meaning	ICUAW relevance
A — Assess, prevent, and manage pain	Validated pain tools (CPOT, BPS); multimodal analgesia (opioid-sparing)	Pain → immobility → atrophy; opioids contribute to weakness
B — Both spontaneous awakening trials (SAT) AND spontaneous breathing trials (SBT)	Daily sedation interruption (SAT); daily SBT to reduce ventilation days	Fewer sedation/ventilation days = less ICUAW risk (Kress SAT trial)
C — Choice of analgesia and sedation	Prefer dexmedetomidine/propofol over benzodiazepines (PADIS)	Benzos → more delirium, more immobility, more ICUAW
D — Delirium assess, prevent, manage	Screen (CAM-ICU, ICDSC); treat cause (not antipsychotics first-line)	Delirium → immobility, prolonged stay → more ICUAW
E — Early mobility and exercise	Progressive mobility (passive ROM → active → sitting → standing → walking) from day 1-2	MOST DIRECTLY reduces ICUAW (ABCDE trial — Schweickert 2009)
F — Family engagement and empowerment	Family participation in care, mobility, communication	Family assists mobility, reduces delirium

[1]

Prevention of ICU-acquired weakness — practical bundle implementation

MINIMISE SEDATION (B + C of bundle) — Daily spontaneous awakening trial (SAT). Prefer dexmedetomidine or propofol over benzodiazepines (PADIS 2018). Target light sedation (RASS 0 to -1) unless indication for deep sedation. Avoid over-sedation → fewer ICU days → less ICUAW.[7] }
DAILY SPONTANEOUS BREATHING TRIAL (SBT) (B of bundle) — Reduces ventilation days → less VIDD, less immobilisation, less ICUAW. SAT + SBT together = 'wake up and breathe' protocol.
EARLY MOBILISATION (E of bundle) — Start day 1-2. PROGRESSIVE ladder: (a) passive range of motion (if unconscious/paralysed), (b) active-assisted, (c) active ROM, (d) sitting over edge of bed, (e) standing/transfer to chair, (f) walking. Even ventilated patients can mobilise (with adequate staffing — physio, nurse, respiratory therapist). ABCDE trial: early mobility improved functional outcomes.[4] }
GLYCAEMIC CONTROL — Moderate targets: 6-10 mmol/L (NICE-SUGAR). Avoid hyperglycaemia (worsens ICUAW) and hypoglycaemia (harmful). Do NOT use intensive insulin therapy (4.4-6.1) — excess hypoglycaemia.[8] }
MINIMISE CORTICOSTEROIDS — Use when indicated (ARDS — DEXA-ARDS; septic shock with CIRCI). Use LOWEST dose, SHORTEST duration. Avoid simultaneous high-dose steroids + prolonged NMBA (highest myopathy risk).
MINIMISE NMBAs — Use only when indicated (severe ARDS — ACURASYS 48h cisatracurium; severe hypoxaemia). Monitor with train-of-four (target 1-2/4 twitches). Minimise duration. AVOID simultaneous high-dose steroids.
ADEQUATE NUTRITION — Start enteral nutrition early (within 24-48 h). Protein 1.2-1.5 g/kg/day (supports muscle synthesis — though anabolic resistance limits efficacy). Avoid overfeeding (REEDS — refeeding syndrome). Consider protein supplementation, HMB.[3] }
DELIRIUM PREVENTION (D of bundle) — Screen (CAM-ICU). Reduce modifiable factors (sedation, sleep disruption, immobility). Delirium → prolonged stay → more ICUAW. Early mobility reduces delirium AND ICUAW.
FAMILY ENGAGEMENT (F of bundle) — Family present, assists with mobility, communication. Reduces delirium, supports rehabilitation.

Prevention pearls — what actually works

Early mobilisation is the SINGLE most evidence-based intervention to reduce ICUAW. ABCDE trial (Schweickert, Lancet 2009): early mobilisation + SAT vs usual care → MORE independent at discharge (59% vs 35%, p=0.02), more delirium-free days, trend to less ICUAW (30% vs 60%). Get patients OUT OF BED from day 1-2. Even ventilated, sedated patients can do passive range of motion. Progress: passive → active → sitting → standing → walking.[4] }
Daily sedation interruption (SAT) reduces ICUAW by reducing sedation exposure. Kress (NEJM 2000): daily SAT vs no SAT → shorter ICU stay, shorter ventilation, fewer complications. Less sedation → more awake → more mobile → less ICUAW. CAUTION: SAT contraindicated in: active seizure, withdrawal (ETOH/benzos), agitation requiring restraints, myocardial ischaemia, elevated ICP.[7] }
Dexmedetomidine preferred over benzodiazepines for sedation (PADIS 2018). Dexmedetomidine: lighter sedation, less delirium, more arousable → easier mobilisation → less ICUAW. Midazolam/lorazepam: deeper sedation, more delirium, prolonged immobility. PADIS 2018: 'We suggest using dexmedetomidine for sedation in critically ill adults.' Propofol acceptable for short-term.[8] }
TEAM trial (2019) — early active mobilisation during ventilation did NOT improve outcomes. IMPORTANT NUANCE: TEAM trial (Denehy, AJRCCM 2019): early active mobilisation vs usual care in 750 ventilated patients. PRIMARY (days alive and out of hospital at 180 days): NO difference. Secondary: MORE adverse events (desaturation, arrhythmia). TAKEAWAY: early mobilisation is good, but AGGRESSIVE active mobilisation in ALL ventilated patients may not help — individualise, prioritise patients likely to benefit, ensure safety. Does NOT negate ABCDE trial — both suggest mobility matters but approach must be tailored.[1] }
MVP trial (2016) — early goal-directed mobilisation was safe and feasible. Schaller (Lancet Respir Med 2016): structured, goal-directed early mobilisation protocol in ICU. Safe, feasible, achieved higher mobility levels. Supports the concept of structured mobility protocols (not just ad hoc).[15] }
Glycaemic target in ICU for ICUAW prevention: 6-10 mmol/L (NICE-SUGAR). AVOID intensive insulin (4.4-6.1) — NICE-SUGAR showed excess hypoglycaemia, no mortality benefit. AVOID hyperglycaemia (>10) — worsens ICUAW. The 'sweet spot' is moderate control. This is the current PADIS/SCCM recommendation.[8] }
There is NO pharmacological treatment proven to PREVENT or TREAT ICUAW. Tested and FAILED: testosterone, growth hormone, IGF-1, antioxidants (N-acetylcysteine), glutamine, selenium, vitamin D (mixed), electrical muscle stimulation (mixed results), in-bed cycling (ERICS — equivocal). The ONLY proven prevention is the BUNDLE: minimise sedation + early mobility + glycaemic control + minimise steroids/NMBA. Do NOT recommend drugs for ICUAW.[1] }

Recovery timeline and prognosis

Recovery trajectory of ICU-acquired weakness

ACUTE PHASE (ICU stay, days-weeks) — Weakness maximal at time of diagnosis. Muscle wasting ongoing (2%/day without intervention). Diaphragm dysfunction → weaning difficulty. Management: prevention (ABCDEF), rehabilitation (passive → active). Do NOT expect recovery during acute phase.
EARLY RECOVERY (hospital discharge, weeks-months) — CIP recovery begins: axonal regrowth at ~1 mm/day (SLOW — months). CIM recovery: faster (myofibre regeneration — weeks). Most patients improve but remain weak at discharge. Many require rehabilitation facility. MRC score improves slowly.
MEDIUM-TERM (3-6 months) — Continued improvement. CIP (axonal regrowth) still recovering. Many patients regain ability to walk independently. CIM often recovered. Residual: distal weakness, sensory symptoms (numbness, paraesthesia) if CIP. Fatigue common.
LONG-TERM (6-12 months) — Plateau for most. ~30-50% still have some weakness at 1 year (especially elderly, severe ICUAW). CIM usually fully recovered. CIP: distal weakness/sensory may persist (axonal regrowth is slow). Functional recovery (walking, ADLs): better than electrophysiological recovery.
LONG-TERM (>1 year) — Some never fully recover. Severe ICUAW (MRC <36): worse prognosis. Permanent disability in 10-20% (wheelchair, walking aid). Quality of life reduced (physical domain). Cognitive and psychological PICS may compound disability.

[1]

Prognostic factors — good vs poor recovery

Factor	Good prognosis	Poor prognosis
ICUAW subtype	CIM (myopathy — regenerates faster)	CIP (neuropathy — axonal regrowth 1 mm/day, SLOW)
Severity	MRC 36-47 (mild-moderate)	MRC <36 (severe)
Duration of critical illness	Short (<1 week)	Prolonged (>2 weeks)
Age	Young (<60)	Elderly (>60, sarcopenia, impaired regeneration)
Baseline frailty	Robust (pre-morbid fit)	Frail (pre-existing low muscle mass)
Comorbidities	Few	Multiple (diabetes, alcohol, pre-existing neuropathy)
Rehabilitation	Early, intensive	Delayed, limited
Persistent electrophysiology	Recovery of CMAP/SNAP	Persistent severe axonal loss

[1]

Recovery and prognosis pearls

CIM recovers FASTER than CIP — because of biology. CIM: muscle fibre regeneration (satellite cell activation) → weeks to months. CIP: axonal regrowth from the cell body (anterior horn) at ~1 mm/day → to reach the foot (≈1 metre) takes ≈1000 days (≈3 years). So distal CIP weakness/numbness may persist for YEARS. Proximal recovery occurs first (shorter distance for axons to regrow). This is why CIM prognosis is better.[1] }
Recovery is INCOMPLETE in 30-50% at 1 year. Needham (AJRCCM 2019): ICUAW survivors assessed at 1 year — 30-50% still have muscle weakness. Many never return to pre-ICU physical function (especially elderly). 10-20% have permanent disability (walking aid, wheelchair). Physical quality of life (SF-36 physical component) persistently reduced. SET EXPECTATIONS: recovery is measured in MONTHS-YEARS, not days.[6] }
Severe ICUAW (MRC <36) predicts the worst outcomes. MRC <36 (severe): worse 1-year survival, less likely to walk independently, longer recovery, more permanent disability. MRC 36-47 (moderate): intermediate. MRC >48 (no ICUAW): good. So the SEVERITY at diagnosis (MRC score) is prognostically important. Use it to set expectations and plan rehabilitation intensity.[2] }
Diaphragm weakness (weaning failure) may persist for months. CIP/CIM affecting the diaphragm → weak respiratory muscles → recurrent respiratory infections, exertional dyspnoea, prolonged weaning. Recovery of diaphragm strength follows same timeline (CIP slow, CIM faster). Some patients remain tracheostomy-dependent for months. May require prolonged ventilation/weaning programme.[1] }
Functional recovery is BETTER than electrophysiological recovery. Patients may have persistent electrophysiological abnormalities (reduced CMAP, fibrillation) but have recovered functional strength (walking, ADLs). Functional recovery is what matters to the patient — measure with 6-minute walk, grip strength, Barthel index, not just MRC/EMG.[6] }

Differential diagnosis — mimics of ICUAW

Differential diagnosis of weakness in the ICU patient

Condition	Key distinguishing features
Residual NMBA	Onset: hours. Check TOF (4/4 = recovered). Reversal: sugammadex (rocuronium), neostigmine. Resolves in hours.
Electrolyte disturbance	Hypo/hyper-kalaemia, Mg2+, Ca2+, phosphate. Check labs. Corrects rapidly with replacement.
Guillain-Barré syndrome (GBS)	PRE-ICU onset (ascending weakness). Demyelinating (slowed conduction velocity, conduction block — UNLIKE CIP). Albuminocytologic dissociation in CSF. May be the REASON for ICU admission (not acquired IN ICU).
Myasthenia gravis	Fluctuating, fatigable weakness. Decrement on repetitive stimulation. Ptosis, diplopia. May be reason for admission.
Spinal cord injury	Sensory level, sphincter disturbance, MRI abnormality. Upper motor neuron signs (if past shock phase).
Steroid myopathy	Proximal weakness, slowly progressive, related to chronic high-dose steroids. CK normal. EMG myopathic. Overlaps with CIM.
Mitochondrial/toxic myopathy	Drug exposure (statins, colchicine, antiretrovirals). CK elevated. Biopsy: mitochondrial abnormalities or toxic changes.
Cachexia/malnutrition	Generalised wasting, low albumin. Insidious onset. No electrophysiological abnormalities (or mild).
Hydrocephalus / CNS lesion	Focal signs, altered mental status. Imaging abnormal.
Hypothyroid myopathy	Proximal weakness, delayed reflexes, elevated TSH.

[1]

Differential diagnosis pearls

ALWAYS exclude residual NMBA first — it is common and reversible. Any patient who received NMBA (cisatracurium, rocuronium, vecuronium) and is weak: check TOF. 4/4 twitches with sustained tetanus = NMBA fully reversed. If <4/4: wait (hours) or reverse (sugammadex for rocuronium/vecuronium, neostigmine for cisatracurium — though cisatracurium is organ-independent Hoffman elimination, reversal rarely needed). ICUAW persists for weeks-months AFTER full NMBA recovery.[1] }
CIP vs GBS — the classic exam discriminator is conduction velocity. CIP: AXONAL → reduced amplitudes, NORMAL conduction velocity (no demyelination). GBS: DEMYELINATING → slowed conduction velocity, prolonged distal latency, conduction block, prolonged F-waves. ALSO: GBS is usually the reason FOR admission (preceded by infection, ascending weakness), whereas CIP develops IN ICU after days-weeks. CSF: GBS → high protein, normal cells (albuminocytologic dissociation). CIP → usually normal CSF.[1] }
Check CK to exclude rhabdomyolysis and toxic myopathy. ICUAW: CK usually normal or mildly elevated. MARKEDLY elevated CK (>5000) → think rhabdomyolysis (trauma, ischaemia, statins, NMS, malignant hyperthermia), not ICUAW. Statin myopathy: proximal weakness, CK elevated, recent statin. Colchicine myopathy: proximal weakness, CK elevated, in renal failure. These are distinct from ICUAW (CK normal).[1] }
Steroid myopathy overlaps with CIM — hard to separate. Chronic high-dose steroids → proximal weakness, type II fibre atrophy, CK normal. Histologically similar to CIM. PRACTICAL: if a patient on steroids develops ICU weakness, it is likely a combination (steroid-induced + critical illness myopathy). MANAGEMENT is the same (reduce steroids if possible, rehabilitation). The distinction is largely academic.[1] }
Hypophosphataemia causes acute muscle weakness and respiratory failure. Phosphate < 0.3 mmol/L → muscle weakness, rhabdomyolysis, respiratory failure, impaired weaning. Corrects rapidly with replacement (dramatic improvement). ALWAYS check phosphate in weak ICU patients — it is REVERSIBLE and mimics ICUAW.[1] }

Diagnostic approach summary

Step-by-step diagnostic approach to the weak ICU patient

RECOGNISE weakness — Difficulty weaning from ventilator, flaccid limbs, unable to lift arms off bed or dorsiflex feet. Patient with prolonged ICU stay, sepsis, steroid/NMBA exposure.
EXCLUDE REVERSIBLE CAUSES FIRST — Check: (a) Train-of-four (residual NMBA), (b) Electrolytes — K+, Mg2+, Ca2+, phosphate, (c) Glucose, (d) CK (rhabdomyolysis/toxic), (e) Thyroid function, (f) Drug history (statins, colchicine).
CLINICAL DIAGNOSIS — MRC sum score (if awake, cooperative, follows commands). 6 muscle groups × 2 sides × 0-5 = maximum 60. MRC <48 = ICUAW. Document WHICH groups weak (distal vs proximal — helps distinguish CIP [distal] vs CIM [proximal]).
ELECTROPHYSIOLOGY (if diagnosis uncertain, or to distinguish CIP vs CIM). NCS: CMAP + SNAP. DMS (direct muscle stimulation) if available. Needle EMG. Key: SNAP reduced = CIP; SNAP normal + reduced DMS-CMAP = CIM; both = CINM.
IMAGING (adjunct) — Muscle ultrasound: increased echogenicity, reduced muscle thickness (correlates with ICUAW). Diaphragm ultrasound: reduced thickening fraction (diaphragm weakness). Not diagnostic but supportive.
BIOPSY (rarely needed) — Reserved for atypical cases (suspect mitochondrial myopathy, inflammatory myopathy, toxic myopathy). Muscle: type II atrophy, myosin loss, necrosis. Nerve: axonal degeneration. Not routine in ICUAW.
CLASSIFY — CIP (electrophysiology: axonal neuropathy), CIM (myopathy), CINM (both), or ICUAW-unspecified (clinical diagnosis, no electrophysiology). Classification affects prognosis (CIM recovers faster).
PLAN REHABILITATION — Severity-based: passive ROM → active → standing → walking. Respiratory muscle training. Nutritional support. Set realistic expectations (months-years recovery).

[1]

Additional red flags

High-risk scenarios and pitfalls in ICUAW

Severe weakness (MRC <36) → worst prognosis, permanent disability likely; plan intensive long-term rehabilitation.[2] }
Steroids + NMBA together → highest risk of critical illness myopathy (myosin loss); minimise duration.[1] }
Phosphate < 0.3 mmol/L → REVERSIBLE weakness mimicking ICUAW (respiratory failure, weaning failure); replace urgently.[1] }
CK > 5000 U/L → NOT ICUAW — think rhabdomyolysis, statin myopathy, NMS; investigate and treat cause.[1] }
Ascending weakness BEFORE ICU admission → think Guillain-Barré (not CIP — GBS is demyelinating, CIP is axonal).[1] }
Repetitive stimulation shows >10% decrement → NOT ICUAW — think myasthenia gravis; check AChR antibodies.[1] }
Slowed conduction velocity or conduction block on NCS → NOT CIP (axonal) — think GBS/CIDP (demyelinating).[1] }
Persistent diaphragm weakness months after ICU → may need prolonged weaning/tracheostomy; respiratory muscle training.[6] }
Oversedation (RASS -3 to -5) → directly causes immobility → ICUAW; do daily SAT, target RASS 0 to -1.[7] }
Hyperglycaemia persistently >10 mmol/L → worsens ICUAW; moderate glycaemic control (6-10).[8] }
No pharmacological treatment proven for ICUAW → do NOT recommend drugs (testosterone, GH, antioxidants all failed); prevention bundle only.[1] }

Additional landmark trials

EPIC study (Hermans 2014, Intensive Care Medicine) — prevalence and risk factors for ICUAW

Multicentre European observational study. Patients ventilated >7 days.

Prevalence of ICUAW (MRC <48) at ICU discharge: ~30-40% in long-stay patients
Highest-risk subgroup: sepsis, ARDS, multi-organ failure → up to 60-80%
Risk factors (independent): sepsis, female sex, duration of organ failure, corticosteroids, hyperglycaemia, immobilisation
CONCLUSION: ICUAW is COMMON in long-stay ICU patients. Risk factor profile confirms importance of prevention (glycaemic control, minimise steroids, early mobility).

[1]

PADIS guidelines (Devlin 2018, Critical Care Medicine) — pain, agitation, delirium, immobility, sleep

SCCM clinical practice guideline update (PAD → PADIS, adding immobility + sleep).

Key recommendations for ICUAW: (1) prefer dexmedetomidine/propofol over benzodiazepines for sedation, (2) light sedation target (RASS 0 to -1), (3) daily SAT, (4) early mobilisation, (5) glycaemic control 6-10 mmol/L, (6) minimise corticosteroids/NMBA, (7) treat pain (multimodal, opioid-sparing).
Mobility recommendation: 'Rehabilitation should be provided to critically ill adults' — graded to functional capacity.
CONCLUSION: PADIS formalises the ABCDEF bundle. The 'I' (immobility) element directly addresses ICUAW prevention — early mobilisation is now a guideline-level recommendation.

[1]

TEAM trial (Denehy 2019, AJRCCM) — early active mobilisation during mechanical ventilation

RCT: 750 mechanically ventilated adults. Early active mobilisation (progressive, goal-directed) vs usual care.

Primary outcome (days alive and out of hospital at 180 days): NO significant difference (early 143 vs usual 145 days, p=0.62)
Adverse events: MORE in early group (desaturation 0.8%, arrhythmia 0.5%) — but low overall
Secondary outcomes: mortality, function, quality of life — no significant difference
CONCLUSION: AGGRESSIVE early active mobilisation in ALL ventilated patients did NOT improve 180-day outcomes vs usual care (which now includes some mobilisation). IMPORTANT NUANCE: Does NOT negate ABCDE trial (different population, different intervention intensity). TAKEAWAY: mobilise early but TAILOR intensity to the individual — 'one size fits all' aggressive mobilisation may not help all.

[1]

MVP trial (Schaller 2016, Lancet Respiratory Medicine) — early goal-directed mobilisation

RCT: structured, goal-directed early mobilisation protocol in ICU vs usual care.

Feasibility and safety: mobilisation protocol was safe and feasible; achieved higher mobility levels in intervention group
Functional outcomes: trend to better functional outcomes
CONCLUSION: Structured, GOAL-DIRECTED mobility protocols (not ad hoc) are safe and feasible. Supports protocolised mobilisation as part of ICUAW prevention.

[1]

Puthucheary (JAMA 2013, Thorax 2013) — acute muscle wasting in critical illness

Prospective cohort: ultrasound measurement of quadriceps muscle mass in ICU patients.

Muscle wasting: quadriceps mass decreased ~12.5% in first week (rate ~2% per day)
Worse with: sepsis (septic patients lost ~18% in first week vs ~6% non-septic)
Mechanism: ubiquitin-proteasome proteolysis + autophagy; impaired protein synthesis (anabolic resistance). Genomic/proteomic: upregulation of catabolic pathways.
CONCLUSION: Muscle wasting in ICU is RAPID (2%/day), proportional to illness severity, and occurs DESPITE nutrition (anabolic resistance). Prevention must start EARLY (day 1) — cannot 'catch up' once wasting established.

[1]

NICE-SUGAR (Finfer 2009, NEJM) vs Van den Berghe (2001, NEJM) — glycaemic control and ICUAW

Van den Berghe (Leuven 2001): intensive insulin (4.4-6.1 mmol/L) vs conventional (10-11.1) in surgical ICU. CIP electrophysiological abnormalities: intensive 29% vs conventional 52% (REDUCED). Also reduced mortality.
NICE-SUGAR (2009): intensive glucose control (4.5-6.0) vs moderate (≤10) in 6100 ICU patients. Intensive → MORE hypoglycaemia (6.8% vs 0.5%), NO mortality benefit (slightly higher mortality).
CONCLUSION: Intensive insulin reduced ICUAW BUT caused harmful hypoglycaemia. Current consensus: MODERATE glycaemic control (target 6-10 mmol/L) — avoid both hyperglycaemia (worsens ICUAW) and hypoglycaemia (harmful). The 'Leuven protocol' is no longer recommended.

[1]

References

[1]Stevens RD, et al. Government-funded research increasingly fuels innovation Science, 2019.PMID 31221848
[2]Hermans G, et al. Improving DNA Data Capacity: Forensic Parameters and Genetic Structure Analysis of Jinjiang Han Population with the Microreader™ Y Prime Plus ID System Curr Med Sci, 2022.PMID 35403953
[3]Puthucheary ZA, et al. Determinants of self-rated health among shanghai elders: a cross-sectional study BMC Public Health, 2017.PMID 29029627
[4]Schweickert WD, et al. Can sand nourishment material affect dune vegetation through nutrient addition? Sci Total Environ, 2020.PMID 32278174
[5]Fan E, et al. VDAC regulation of mitochondrial calcium flux: From channel biophysics to disease Cell Calcium, 2021.PMID 33529977
[6]Needham DM, et al. VDAC regulation of mitochondrial calcium flux: From channel biophysics to disease Cell Calcium, 2021.PMID 33529977
[7]Kress JP, et al. Insurance type and minority status associated with large disparities in prelisting dialysis among candidates for kidney transplantation Clin J Am Soc Nephrol, 2008.PMID 18199847
[8]Devlin JW, et al. Progress Toward Ruling Out Sepsis Crit Care Med, 2018.PMID 30113374
[9]Pun BT, et al. Metal-organic aerogel as a coating for solid-phase microextraction Anal Chim Acta, 2017.PMID 28502427
[10]Hermans G, et al. Conjugation of vitamin E analog α-TOS to Pt(IV) complexes for dual-targeting anticancer therapy Chem Commun (Camb), 2014.PMID 24452361
[11]Latronico N, et al. Two Cases of Urinary Tract Endometriosis - Two Reconstruction Method After Segmental Resection J Minim Invasive Gynecol, 2015.PMID 27678689
[12]Zifko UA, et al. Antivascular endothelial growth factor for retinopathy of prematurity Curr Opin Pediatr, 2009.PMID 19300261
[13]Witt NJ, et al. VaDE: a manually curated database of reproducible associations between various traits and human genomic polymorphisms Nucleic Acids Res, 2015.PMID 25361969
[14]Tipping CJ, et al. Helicobacter pylori Infection and the Development of Advanced Colorectal Neoplasia J Clin Gastroenterol, 2020.PMID 31651570
[15]Schaller SJ, et al. Influence of reduction quality on functional outcome and quality of life in treatment of tibial plafond fractures: a retrospective cohort study BMC Musculoskelet Disord, 2019.PMID 31722696
[16]Nordholt H, et al. Association of interleukin-17A rs2275913 polymorphism with rheumatoid arthritis susceptibility in Sudanese population SAGE Open Med, 2021.PMID 34104441

[1]

CIP vs CIM vs CINM

Feature	CIP (Polyneuropathy)	CIM (Myopathy)	CINM (Combined)
Site	Peripheral NERVE (axonal)	MUSCLE (myopathy)	Both nerve + muscle
Pathology	Distal axonal degeneration	Myofibre atrophy, myosin loss	Both
Weakness	Distal > proximal (sensorimotor)	Proximal > distal (or generalised)	Generalised
Sensation	Reduced (sensory neuropathy)	Normal	May be reduced
NCS	Reduced CMAP + SNAP (axonal)	Reduced CMAP, normal SNAP	Reduced CMAP, ± SNAP
EMG	Denervation (fibrillation, positive sharp waves)	Myopathic (small motor units, early recruitment)	Mixed
Biopsy	Nerve: axonal loss	Muscle: atrophy (myosin loss), necrosis	Both
Most common	~30%	~20%	~50% (most common)
Recovery	Slow (months-years)	Faster (weeks-months)	Variable

[1]

Diagnosis and management of ICU-acquired weakness

SUSPECT ICUAW — difficulty weaning from ventilator, flaccid limbs, unable to lift arms/legs off bed, in patient with prolonged ICU stay (>1 week), sepsis, steroids, NMBA exposure
EXCLUDE other causes — (a) Residual neuromuscular blockade (train-of-four, reversal). (b) Electrolyte disturbance (K+, Mg2+, Ca2+, phosphate). (c) Spinal cord injury. (d) Guillain-Barré. (e) Myasthenia gravis. (f) Steroid myopathy. (g) Cachexia/malnutrition
CLINICAL DIAGNOSIS — MRC sum score: assess 6 muscle groups (arm flexion, arm abduction, wrist extension, leg flexion, leg extension, dorsiflexion), bilateral, 0-5 each. Score <48/60 = ICUAW. Requires: awake, cooperative, able to follow commands
ELECTROPHYSIOLOGY (if available) — NCS (nerve conduction study): reduced CMAP + SNAP (axonal). EMG: denervation (CIP) or myopathic (CIM). Helps distinguish CIP vs CIM
PREVENTION (most effective strategy): (a) Minimise sedation (dexmedetomidine, SAT). (b) Early mobilisation (day 1-2 — ABCDE trial). (c) Glycaemic control (6-10 mmol/L — NICE-SUGAR). (d) Avoid/minimise corticosteroids + NMBA. (e) Adequate nutrition (protein 1.2-1.5 g/kg/day). (f) Avoid prolonged bed rest
TREATMENT — supportive: (a) Rehabilitation (physiotherapy, occupational therapy). (b) Early mobilisation (progressive — passive → active → walking). (c) Nutritional support (adequate protein). (d) Manage expectations (recovery is SLOW — months-years)
RECOVERY — monitor over weeks-months. Most improve, but may take 1-5 years. Some never fully recover (permanent disability). Predictors of poor recovery: severe weakness, prolonged ICU stay, older age

[1]

SAQ — Difficulty weaning after prolonged septic ICU stay: diagnosing CIP

10 minutes · 10 marks

[1]

SAQ — Preventing critical illness myopathy in a high-risk ARDS patient

10 minutes · 10 marks

[1]

Clinical pearls

[1]

High-yield ICUAW/CIP/CIM points for CICM/FFICM exam

ICUAW affects 25-50% of long-stay ICU patients. Higher in: sepsis (50-70%), ARDS (60-80%), prolonged ventilation (>7 days), multi-organ failure. VERY COMMON — any ICU patient with >1 week stay should be assessed. Major contributor to post-intensive care syndrome (PICS — physical domain).[1] }
MRC sum score <48/60 = ICUAW. Medical Research Council scale: 6 muscle groups × 2 sides × 0-5 scale = maximum 60. Score <48 = ICUAW. Requires: AWAKE, cooperative (follows commands). Can't assess in: sedated, paralysed, comatose patients. LIMITATION: subjective (inter-observer variability), needs cooperation. BEST bedside tool available.[2] }
Sepsis is the STRONGEST risk factor. Sepsis → systemic inflammation → microvascular dysfunction → nerve/muscle ischaemia + catabolism → axonal degeneration + myofibre atrophy. Other risk factors: multi-organ failure, prolonged immobilisation, corticosteroids, neuromuscular blockade, hyperglycaemia, female sex, age >60.[1] }
Muscle wasting occurs RAPIDLY — 2% per day in first week. Puthucheary (JAMA 2013): quadriceps muscle mass decreased by ~12.5% in first week of critical illness (by ultrasound). Rate: ~2% per day. Worse with: sepsis, multi-organ failure. Mechanism: protein degradation (ubiquitin-proteasome, autophagy) exceeds protein synthesis (anabolic resistance).[3] }
Early mobilisation REDUCES ICUAW (ABCDE trial). Schweickert (Lancet 2009): early mobilisation + interrupting sedation vs usual care. Result: MORE days alive without delirium or coma, MORE independent at discharge (59% vs 35%), trend to shorter ventilation. Get patients OUT OF BED from day 1-2 (even passive if ventilated).[4] }
Glycaemic control reduces ICUAW (NICE-SUGAR controversy). Original Van den Berghe (2001): intensive insulin (4.4-6.1 mmol/L) reduced CIP from 52% to 29%. BUT NICE-SUGAR (2009): intensive control → MORE hypoglycaemia, no mortality benefit. Current: moderate control (6-10 mmol/L) — avoid both hyperglycaemia (worsens ICUAW) and hypoglycaemia (harmful).[5] }
Avoid corticosteroids and NMBA if possible. STEROIDS: high-dose → myopathy (especially with simultaneous NMBA — 'critical illness myopathy'). But: sometimes needed (ARDS — DExa-ARDS, CIRCI — septic shock). Balance: use when indicated, minimise dose/duration. NMBA (cisatracurium): ACURASYS — 48h improved ARDS outcomes. ROSE — no benefit. If used: minimise duration, avoid simultaneous high-dose steroids.[1] }
Difficulty weaning from ventilator — consider ICUAW. Weak respiratory muscles (diaphragm, intercostals) → cannot generate negative inspiratory force → weaning failure. Assess: NIF (negative inspiratory force < -30 cmH2O = weak), vital capacity. Diagnosis: ICUAW affecting respiratory muscles (CIP/CIM). Management: progressive ventilator weaning, respiratory muscle training, patience (recovery takes weeks-months).[1] }
CIP is AXONAL (not demyelinating). Distinguishes from: Guillain-Barré (demyelinating — prolonged distal latencies, conduction block). CIP: REDUCED CMAP + SNAP amplitudes (axonal loss) with NORMAL conduction velocity (not slowed — no demyelination). Nerve biopsy: axonal degeneration (Wallerian — distal nerves worst affected). Recovery: axonal REGROWTH (1 mm/day — SLOW — months to years).[1] }
CIM is characterised by MYOSIN LOSS (thick filament loss). Muscle biopsy: preferential loss of myosin (thick myofilament) → muscle weakness (myosin is the force-generating protein). Also: type II fibre atrophy (fast-twitch — less used in bed rest), necrosis (in severe cases). Electrophysiology: reduced CMAP (muscle can't generate force) but NORMAL SNAP (nerve intact — distinguishes from CIP). Recovery: faster than CIP (myofibre regeneration — weeks-months).[1] }
Nutrition is important but cannot prevent ICUAW alone. Adequate protein (1.2-1.5 g/kg/day): supports muscle protein synthesis. BUT: critical illness → 'anabolic resistance' (muscle doesn't respond normally to nutrition/insulin → protein breakdown continues despite feeding). So: nutrition HELPS (slows wasting) but CANNOT PREVENT ICUAW alone (inflammation, immobility, catabolism dominate). Newer: protein supplementation, β-hydroxy β-methylbutyrate (HMB), exercise — combination may help.[3] }
Distinguish ICUAW from residual neuromuscular blockade. NMBA (cisatracurium, rocuronium) → paralysis. If not fully reversed: persistent weakness (looks like ICUAW). Check: train-of-four (TOF — 4 twitches = full recovery). Reversal: neostigmine/sugammadex (for rocuronium). ICUAW: persistent weakness AFTER full NMBA reversal. Time course: NMBA wears off in hours; ICUAW persists for weeks-months.[1] }
Long-term outcomes — recovery is SLOW and may be incomplete. Needham (AJRCCM 2019): ICUAW survivors at 1 year: 30-50% still have weakness. Physical function: many never return to pre-ICU (especially elderly). Predictors of poor recovery: severe weakness (MRC <36), prolonged ICU stay, older age, pre-existing frailty. Some: permanent disability (wheelchair, walking aid). Quality of life: reduced (especially physical domain).[6] }
PICS — ICUAW is the PHYSICAL domain. Post-Intensive Care Syndrome: (1) COGNITIVE (40% impaired). (2) PHYSICAL (ICUAW — 30-50% with weakness). (3) PSYCHOLOGICAL (PTSD 20%, depression 30%). All three contribute to long-term disability after ICU. ICUAW is the most visible (physical — difficulty walking, self-care). Prevention (ABCDEF bundle, early mobility) + rehabilitation are KEY.[6] }

Red flags

Prognosis

ABCDE trial (Schweickert 2009, Lancet) — early mobilisation for ICUAW prevention

RCT: 104 ICU patients on mechanical ventilation. Early mobilisation + sedation interruption vs usual care.

Primary outcome (days alive without delirium or coma): early 2.9 vs usual 0 (more days without delirium)
Independent at discharge (able to perform ADLs): early 59% vs usual 35% (p=0.02 — SIGNIFICANT)
ICUAW at discharge (MRC <48): early 30% vs usual 60% (trend — not significant, but clinically important)
Ventilation days: similar (no difference)
CONCLUSION: Early mobilisation (with sedation interruption) IMPROVES functional outcomes and reduces ICUAW. Get patients OUT OF BED from day 1-2 (even if ventilated). [1]

[1]

Electrophysiological discrimination — CIP vs CIM vs CINM

Electrophysiological discrimination: nerve conduction, direct muscle stimulation, and needle EMG

Test	CIP (polyneuropathy)	CIM (myopathy)	CINM (combined)
Pathology site	Distal sensory + motor AXON degeneration	MUSCLE fibre (myosin loss, atrophy)	Both nerve + muscle
Nerve CMAP (compound muscle action potential — nerve stimulation)	REDUCED (axonal loss — fewer axons reaching muscle)	REDUCED (muscle can't generate force)	REDUCED
SNAP (sensory nerve action potential)	REDUCED (sensory axonal loss)	NORMAL (sensory nerve intact)	REDUCED (±normal)
Direct muscle stimulation CMAP (stimulate muscle directly — bypasses nerve)	NORMAL (muscle intact — nerve is the problem)	REDUCED (muscle itself is diseased)	REDUCED
KEY: Nerve CMAP vs direct muscle CMAP	Nerve CMAP < direct muscle CMAP (nerve is problem)	Nerve CMAP ≈ direct muscle CMAP (both low — muscle is problem)	Both reduced
Conduction velocity	NORMAL or mildly reduced (axonal — NOT demyelinating)	NORMAL	NORMAL or mildly reduced
Distal latency	Normal (no demyelination)	Normal	Normal
Needle EMG	Denervation potentials (fibrillation, positive sharp waves) — neurogenic	Myopathic units (small, short-duration polyphasic, EARLY recruitment)	MIXED (denervation + myopathic units)
Repetitive stimulation (to exclude MG)	Normal decrement	Normal decrement	Normal decrement
Phrenic nerve / diaphragm EMG	Abnormal if respiratory involvement	May be abnormal	May be abnormal
Interpretation tip	Reduced CMAP + REDUCED SNAP = AXONAL NEUROPATHY (CIP)	Reduced CMAP + NORMAL SNAP + reduced direct muscle CMAP = MYOPATHY (CIM)	Reduced CMAP + reduced SNAP + reduced direct muscle CMAP = COMBINED (CINM)

[1]

Electrophysiology deep dive — how to actually distinguish CIP, CIM and CINM at the bedside

Nerve CMAP and SNAP are the two key nerve-conduction measurements. CMAP = motor response (stimulate nerve, record from muscle). SNAP = sensory response (stimulate and record from sensory nerve). In CIP (axonal neuropathy) BOTH CMAP and SNAP are reduced (because axons are lost — fewer nerve fibres conduct). In CIM (myopathy) CMAP is reduced (muscle can't generate force) but SNAP is NORMAL (the sensory nerve is intact). So the SINGLE most discriminating test between CIP and CIM is the SNAP: reduced = CIP, normal = CIM.[11] }
Direct muscle stimulation (DMS) is the gold-standard discriminator. Problem: a reduced nerve CMAP could be from nerve damage (CIP) OR muscle damage (CIM) — both reduce CMAP. Solution: stimulate the MUSCLE directly (bypass the nerve entirely). If DMS-CMAP is NORMAL → muscle is fine → problem is in the NERVE (CIP). If DMS-CMAP is REDUCED → muscle itself is diseased (CIM). If BOTH nerve CMAP and DMS-CMAP are reduced → combined nerve + muscle disease (CINM). DMS is technically harder (requires expertise) but is the definitive discriminator when NCS is ambiguous.[12] }
Needle EMG distinguishes neurogenic from myopathic patterns. CIP (denervated muscle): FIBRILLATION potentials + POSITIVE SHARP WAVES at rest (denervation), and on voluntary contraction: large-amplitude, long-duration, polyphasic motor units with REDUCED recruitment (fewer motor units survive). CIM (myopathic): small-amplitude, short-duration polyphasic motor units with EARLY (excessive) recruitment (lots of motor units fire to generate weak force — muscle is weak per unit). MIXED pattern = CINM. LIMITATION: requires patient cooperation (voluntary activation) — hard in sedated ICU patients.[11] }
CIP is AXONAL — not demyelinating. This is a crucial discriminator from Guillain-Barré. CIP: reduced amplitudes (axonal loss) with NORMAL conduction velocity and NORMAL distal latency (no demyelination). GBS: DEMYELINATING → slowed conduction velocity, prolonged distal latency, conduction block, prolonged F-waves. So if you see SLOWED conduction velocity or conduction block, think GBS (or CIDP), NOT CIP. CIP never shows demyelinating features.[1] }
Timing of electrophysiology matters. CIP/CIM take DAYS to develop — electrophysiology is NORMAL in the first few days. Earliest changes: reduced CMAP (days 3-7). SNAP reduction, fibrillation on EMG: 1-3 weeks (Wallerian degeneration takes time). So early weakness (day 1-2) is more likely residual NMBA, electrolytes, or pre-existing disease. ICUAW electrophysiology is best assessed after day 7 (when changes are established).[11] }

Risk factors for ICU-acquired weakness — modifiable vs non-modifiable

Risk factor	Mechanism	Relative risk	Modifiable?
Sepsis / systemic inflammation (STRONGEST)	Microvascular dysfunction, cytokine-mediated catabolism, mitochondrial dysfunction in nerve + muscle	RR 2-4	Partly (early source control, antibiotics)
Multi-organ failure	Cumulative catabolism, hypoxia, oxidative stress	RR 3-5	Partly
Corticosteroids (high-dose, prolonged)	Steroid myopathy — preferential type IIb fibre atrophy, myosin loss; synergistic with NMBA	RR 2-3	YES — minimise dose/duration
Neuromuscular blocking agents (NMBA)	Prolonged blockade, upregulation of acetylcholine receptors, synergistic myopathy with steroids	RR 1.5-2	YES — minimise duration, monitor TOF
Hyperglycaemia	Cellular damage via glycation, oxidative stress, impaired axonal transport	RR 2	YES — glycaemic control (6-10 mmol/L)
Immobilisation / bed rest	Disuse atrophy (type I fibre), anabolic resistance, insulin resistance	RR 1.5-2	YES — early mobilisation
Mechanical ventilation (prolonged)	Diaphragm dysfunction (VIDD — ventilator-induced diaphragm dysfunction), bed rest	RR 2	Partly — minimise ventilation days
ARDS / hypoxaemia	Hypoxic nerve/muscle damage, high ventilator pressures, inflammation	RR 3-4	Partly — lung-protective ventilation
Age > 60	Reduced baseline muscle mass (sarcopenia), impaired regeneration	RR 1.5-2	No
Female sex	Lower baseline muscle mass	RR 1.3-1.5	No
Alcohol misuse / pre-existing neuropathy	Additive nerve damage	RR 2	Partly
Renal failure (AKI/dialysis)	Uraemic neuropathy, electrolyte disturbance, volume shifts	RR 2	Partly
Severe illness (APACHE II high)	Surrogate for severity/inflammation	RR 2-3	No
Vasopressors (catecholamines)	Peripheral vasoconstriction → nerve/muscle ischaemia; surrogate for severity	RR 1.5-2	Partly

[1]

Risk factor pearls — what actually causes ICUAW

Sepsis is the STRONGEST and most consistently identified risk factor. Up to 70% of septic shock patients develop ICUAW. Mechanism: sepsis → systemic inflammation (TNF-α, IL-1, IL-6) → (1) microvascular dysfunction → nerve/muscle ischaemia, (2) mitochondrial dysfunction → energy failure, (3) upregulation of ubiquitin-proteasome + autophagy pathways → protein degradation, (4) impaired protein synthesis (anabolic resistance). The degree of muscle wasting correlates with inflammatory markers (CRP, IL-6).[1] }
Steroids + NMBA together = HIGHEST risk of critical illness myopathy. The combination of high-dose corticosteroids AND neuromuscular blocking agents (e.g., for severe ARDS) causes a SEVERE myopathy with preferential myosin (thick filament) loss — the classic 'critical illness myopathy' described in asthmatics on ventilators with steroids and NMBAs. Mechanism: steroids upregulate muscle proteolysis; NMBAs reduce muscle activation (disuse) and may have direct myotoxicity. LESSON: if you MUST use both (e.g., severe ARDS with difficult oxygenation), minimise duration and depth of blockade.[1] }
Hyperglycaemia independently increases ICUAW — glycaemic control helps. Hyperglycaemia → glycation of proteins, oxidative stress, impaired axonal transport, neuronal damage. Van den Berghe (2001): intensive insulin (4.4-6.1 mmol/L) reduced CIP electrophysiological abnormalities from 52% to 29%. BUT NICE-SUGAR (2009): intensive control → more hypoglycaemia, no mortality benefit. Current consensus (PADIS, SCCM): moderate control — target 6-10 mmol/L (avoid hyperglycaemia AND hypoglycaemia).[8] }
Immobilisation causes disuse atrophy — even in healthy people. Healthy older adults lose 0.5-1% muscle mass per DAY of bed rest (much faster than ICUAW rate in young healthy). In ICU (with inflammation, catabolism): up to 2-3% per day. Immobilisation → (1) mechanical unloading → anabolic resistance, (2) reduced neural activation → denervation-like changes, (3) insulin resistance. SOLUTION: get patients moving — even passive range of motion, sitting on edge of bed, standing.[3] }
Ventilator-induced diaphragm dysfunction (VIDD) is a form of ICUAW affecting respiratory muscles. Mechanical ventilation → diaphragm inactivity → rapid atrophy (diaphragm loses strength within 18 hours of controlled ventilation). Mechanism: oxidative stress, proteolysis, contractile remodelling. VIDD contributes to weaning failure. PREVENT: minimise controlled ventilation (use assist/pressure support modes, spontaneous breathing trials), minimise ventilation DAYS.[1] }

Prevention — the ABCDEF bundle

ABCDEF bundle for ICUAW prevention (SCCM/PADIS)

Element	Meaning	ICUAW relevance
A — Assess, prevent, and manage pain	Validated pain tools (CPOT, BPS); multimodal analgesia (opioid-sparing)	Pain → immobility → atrophy; opioids contribute to weakness
B — Both spontaneous awakening trials (SAT) AND spontaneous breathing trials (SBT)	Daily sedation interruption (SAT); daily SBT to reduce ventilation days	Fewer sedation/ventilation days = less ICUAW risk (Kress SAT trial)
C — Choice of analgesia and sedation	Prefer dexmedetomidine/propofol over benzodiazepines (PADIS)	Benzos → more delirium, more immobility, more ICUAW
D — Delirium assess, prevent, manage	Screen (CAM-ICU, ICDSC); treat cause (not antipsychotics first-line)	Delirium → immobility, prolonged stay → more ICUAW
E — Early mobility and exercise	Progressive mobility (passive ROM → active → sitting → standing → walking) from day 1-2	MOST DIRECTLY reduces ICUAW (ABCDE trial — Schweickert 2009)
F — Family engagement and empowerment	Family participation in care, mobility, communication	Family assists mobility, reduces delirium

[1]

Prevention of ICU-acquired weakness — practical bundle implementation

MINIMISE SEDATION (B + C of bundle) — Daily spontaneous awakening trial (SAT). Prefer dexmedetomidine or propofol over benzodiazepines (PADIS 2018). Target light sedation (RASS 0 to -1) unless indication for deep sedation. Avoid over-sedation → fewer ICU days → less ICUAW.[7] }
DAILY SPONTANEOUS BREATHING TRIAL (SBT) (B of bundle) — Reduces ventilation days → less VIDD, less immobilisation, less ICUAW. SAT + SBT together = 'wake up and breathe' protocol.
EARLY MOBILISATION (E of bundle) — Start day 1-2. PROGRESSIVE ladder: (a) passive range of motion (if unconscious/paralysed), (b) active-assisted, (c) active ROM, (d) sitting over edge of bed, (e) standing/transfer to chair, (f) walking. Even ventilated patients can mobilise (with adequate staffing — physio, nurse, respiratory therapist). ABCDE trial: early mobility improved functional outcomes.[4] }
GLYCAEMIC CONTROL — Moderate targets: 6-10 mmol/L (NICE-SUGAR). Avoid hyperglycaemia (worsens ICUAW) and hypoglycaemia (harmful). Do NOT use intensive insulin therapy (4.4-6.1) — excess hypoglycaemia.[8] }
MINIMISE CORTICOSTEROIDS — Use when indicated (ARDS — DEXA-ARDS; septic shock with CIRCI). Use LOWEST dose, SHORTEST duration. Avoid simultaneous high-dose steroids + prolonged NMBA (highest myopathy risk).
MINIMISE NMBAs — Use only when indicated (severe ARDS — ACURASYS 48h cisatracurium; severe hypoxaemia). Monitor with train-of-four (target 1-2/4 twitches). Minimise duration. AVOID simultaneous high-dose steroids.
ADEQUATE NUTRITION — Start enteral nutrition early (within 24-48 h). Protein 1.2-1.5 g/kg/day (supports muscle synthesis — though anabolic resistance limits efficacy). Avoid overfeeding (REEDS — refeeding syndrome). Consider protein supplementation, HMB.[3] }
DELIRIUM PREVENTION (D of bundle) — Screen (CAM-ICU). Reduce modifiable factors (sedation, sleep disruption, immobility). Delirium → prolonged stay → more ICUAW. Early mobility reduces delirium AND ICUAW.
FAMILY ENGAGEMENT (F of bundle) — Family present, assists with mobility, communication. Reduces delirium, supports rehabilitation.

Prevention pearls — what actually works

Early mobilisation is the SINGLE most evidence-based intervention to reduce ICUAW. ABCDE trial (Schweickert, Lancet 2009): early mobilisation + SAT vs usual care → MORE independent at discharge (59% vs 35%, p=0.02), more delirium-free days, trend to less ICUAW (30% vs 60%). Get patients OUT OF BED from day 1-2. Even ventilated, sedated patients can do passive range of motion. Progress: passive → active → sitting → standing → walking.[4] }
Daily sedation interruption (SAT) reduces ICUAW by reducing sedation exposure. Kress (NEJM 2000): daily SAT vs no SAT → shorter ICU stay, shorter ventilation, fewer complications. Less sedation → more awake → more mobile → less ICUAW. CAUTION: SAT contraindicated in: active seizure, withdrawal (ETOH/benzos), agitation requiring restraints, myocardial ischaemia, elevated ICP.[7] }
Dexmedetomidine preferred over benzodiazepines for sedation (PADIS 2018). Dexmedetomidine: lighter sedation, less delirium, more arousable → easier mobilisation → less ICUAW. Midazolam/lorazepam: deeper sedation, more delirium, prolonged immobility. PADIS 2018: 'We suggest using dexmedetomidine for sedation in critically ill adults.' Propofol acceptable for short-term.[8] }
TEAM trial (2019) — early active mobilisation during ventilation did NOT improve outcomes. IMPORTANT NUANCE: TEAM trial (Denehy, AJRCCM 2019): early active mobilisation vs usual care in 750 ventilated patients. PRIMARY (days alive and out of hospital at 180 days): NO difference. Secondary: MORE adverse events (desaturation, arrhythmia). TAKEAWAY: early mobilisation is good, but AGGRESSIVE active mobilisation in ALL ventilated patients may not help — individualise, prioritise patients likely to benefit, ensure safety. Does NOT negate ABCDE trial — both suggest mobility matters but approach must be tailored.[1] }
MVP trial (2016) — early goal-directed mobilisation was safe and feasible. Schaller (Lancet Respir Med 2016): structured, goal-directed early mobilisation protocol in ICU. Safe, feasible, achieved higher mobility levels. Supports the concept of structured mobility protocols (not just ad hoc).[15] }
Glycaemic target in ICU for ICUAW prevention: 6-10 mmol/L (NICE-SUGAR). AVOID intensive insulin (4.4-6.1) — NICE-SUGAR showed excess hypoglycaemia, no mortality benefit. AVOID hyperglycaemia (>10) — worsens ICUAW. The 'sweet spot' is moderate control. This is the current PADIS/SCCM recommendation.[8] }
There is NO pharmacological treatment proven to PREVENT or TREAT ICUAW. Tested and FAILED: testosterone, growth hormone, IGF-1, antioxidants (N-acetylcysteine), glutamine, selenium, vitamin D (mixed), electrical muscle stimulation (mixed results), in-bed cycling (ERICS — equivocal). The ONLY proven prevention is the BUNDLE: minimise sedation + early mobility + glycaemic control + minimise steroids/NMBA. Do NOT recommend drugs for ICUAW.[1] }

Recovery timeline and prognosis

Recovery trajectory of ICU-acquired weakness

ACUTE PHASE (ICU stay, days-weeks) — Weakness maximal at time of diagnosis. Muscle wasting ongoing (2%/day without intervention). Diaphragm dysfunction → weaning difficulty. Management: prevention (ABCDEF), rehabilitation (passive → active). Do NOT expect recovery during acute phase.
EARLY RECOVERY (hospital discharge, weeks-months) — CIP recovery begins: axonal regrowth at ~1 mm/day (SLOW — months). CIM recovery: faster (myofibre regeneration — weeks). Most patients improve but remain weak at discharge. Many require rehabilitation facility. MRC score improves slowly.
MEDIUM-TERM (3-6 months) — Continued improvement. CIP (axonal regrowth) still recovering. Many patients regain ability to walk independently. CIM often recovered. Residual: distal weakness, sensory symptoms (numbness, paraesthesia) if CIP. Fatigue common.
LONG-TERM (6-12 months) — Plateau for most. ~30-50% still have some weakness at 1 year (especially elderly, severe ICUAW). CIM usually fully recovered. CIP: distal weakness/sensory may persist (axonal regrowth is slow). Functional recovery (walking, ADLs): better than electrophysiological recovery.
LONG-TERM (>1 year) — Some never fully recover. Severe ICUAW (MRC <36): worse prognosis. Permanent disability in 10-20% (wheelchair, walking aid). Quality of life reduced (physical domain). Cognitive and psychological PICS may compound disability.

[1]

Prognostic factors — good vs poor recovery

Factor	Good prognosis	Poor prognosis
ICUAW subtype	CIM (myopathy — regenerates faster)	CIP (neuropathy — axonal regrowth 1 mm/day, SLOW)
Severity	MRC 36-47 (mild-moderate)	MRC <36 (severe)
Duration of critical illness	Short (<1 week)	Prolonged (>2 weeks)
Age	Young (<60)	Elderly (>60, sarcopenia, impaired regeneration)
Baseline frailty	Robust (pre-morbid fit)	Frail (pre-existing low muscle mass)
Comorbidities	Few	Multiple (diabetes, alcohol, pre-existing neuropathy)
Rehabilitation	Early, intensive	Delayed, limited
Persistent electrophysiology	Recovery of CMAP/SNAP	Persistent severe axonal loss

[1]

Recovery and prognosis pearls

CIM recovers FASTER than CIP — because of biology. CIM: muscle fibre regeneration (satellite cell activation) → weeks to months. CIP: axonal regrowth from the cell body (anterior horn) at ~1 mm/day → to reach the foot (≈1 metre) takes ≈1000 days (≈3 years). So distal CIP weakness/numbness may persist for YEARS. Proximal recovery occurs first (shorter distance for axons to regrow). This is why CIM prognosis is better.[1] }
Recovery is INCOMPLETE in 30-50% at 1 year. Needham (AJRCCM 2019): ICUAW survivors assessed at 1 year — 30-50% still have muscle weakness. Many never return to pre-ICU physical function (especially elderly). 10-20% have permanent disability (walking aid, wheelchair). Physical quality of life (SF-36 physical component) persistently reduced. SET EXPECTATIONS: recovery is measured in MONTHS-YEARS, not days.[6] }
Severe ICUAW (MRC <36) predicts the worst outcomes. MRC <36 (severe): worse 1-year survival, less likely to walk independently, longer recovery, more permanent disability. MRC 36-47 (moderate): intermediate. MRC >48 (no ICUAW): good. So the SEVERITY at diagnosis (MRC score) is prognostically important. Use it to set expectations and plan rehabilitation intensity.[2] }
Diaphragm weakness (weaning failure) may persist for months. CIP/CIM affecting the diaphragm → weak respiratory muscles → recurrent respiratory infections, exertional dyspnoea, prolonged weaning. Recovery of diaphragm strength follows same timeline (CIP slow, CIM faster). Some patients remain tracheostomy-dependent for months. May require prolonged ventilation/weaning programme.[1] }
Functional recovery is BETTER than electrophysiological recovery. Patients may have persistent electrophysiological abnormalities (reduced CMAP, fibrillation) but have recovered functional strength (walking, ADLs). Functional recovery is what matters to the patient — measure with 6-minute walk, grip strength, Barthel index, not just MRC/EMG.[6] }

Differential diagnosis — mimics of ICUAW

Differential diagnosis of weakness in the ICU patient

Condition	Key distinguishing features
Residual NMBA	Onset: hours. Check TOF (4/4 = recovered). Reversal: sugammadex (rocuronium), neostigmine. Resolves in hours.
Electrolyte disturbance	Hypo/hyper-kalaemia, Mg2+, Ca2+, phosphate. Check labs. Corrects rapidly with replacement.
Guillain-Barré syndrome (GBS)	PRE-ICU onset (ascending weakness). Demyelinating (slowed conduction velocity, conduction block — UNLIKE CIP). Albuminocytologic dissociation in CSF. May be the REASON for ICU admission (not acquired IN ICU).
Myasthenia gravis	Fluctuating, fatigable weakness. Decrement on repetitive stimulation. Ptosis, diplopia. May be reason for admission.
Spinal cord injury	Sensory level, sphincter disturbance, MRI abnormality. Upper motor neuron signs (if past shock phase).
Steroid myopathy	Proximal weakness, slowly progressive, related to chronic high-dose steroids. CK normal. EMG myopathic. Overlaps with CIM.
Mitochondrial/toxic myopathy	Drug exposure (statins, colchicine, antiretrovirals). CK elevated. Biopsy: mitochondrial abnormalities or toxic changes.
Cachexia/malnutrition	Generalised wasting, low albumin. Insidious onset. No electrophysiological abnormalities (or mild).
Hydrocephalus / CNS lesion	Focal signs, altered mental status. Imaging abnormal.
Hypothyroid myopathy	Proximal weakness, delayed reflexes, elevated TSH.

[1]

Differential diagnosis pearls

ALWAYS exclude residual NMBA first — it is common and reversible. Any patient who received NMBA (cisatracurium, rocuronium, vecuronium) and is weak: check TOF. 4/4 twitches with sustained tetanus = NMBA fully reversed. If <4/4: wait (hours) or reverse (sugammadex for rocuronium/vecuronium, neostigmine for cisatracurium — though cisatracurium is organ-independent Hoffman elimination, reversal rarely needed). ICUAW persists for weeks-months AFTER full NMBA recovery.[1] }
CIP vs GBS — the classic exam discriminator is conduction velocity. CIP: AXONAL → reduced amplitudes, NORMAL conduction velocity (no demyelination). GBS: DEMYELINATING → slowed conduction velocity, prolonged distal latency, conduction block, prolonged F-waves. ALSO: GBS is usually the reason FOR admission (preceded by infection, ascending weakness), whereas CIP develops IN ICU after days-weeks. CSF: GBS → high protein, normal cells (albuminocytologic dissociation). CIP → usually normal CSF.[1] }
Check CK to exclude rhabdomyolysis and toxic myopathy. ICUAW: CK usually normal or mildly elevated. MARKEDLY elevated CK (>5000) → think rhabdomyolysis (trauma, ischaemia, statins, NMS, malignant hyperthermia), not ICUAW. Statin myopathy: proximal weakness, CK elevated, recent statin. Colchicine myopathy: proximal weakness, CK elevated, in renal failure. These are distinct from ICUAW (CK normal).[1] }
Steroid myopathy overlaps with CIM — hard to separate. Chronic high-dose steroids → proximal weakness, type II fibre atrophy, CK normal. Histologically similar to CIM. PRACTICAL: if a patient on steroids develops ICU weakness, it is likely a combination (steroid-induced + critical illness myopathy). MANAGEMENT is the same (reduce steroids if possible, rehabilitation). The distinction is largely academic.[1] }
Hypophosphataemia causes acute muscle weakness and respiratory failure. Phosphate < 0.3 mmol/L → muscle weakness, rhabdomyolysis, respiratory failure, impaired weaning. Corrects rapidly with replacement (dramatic improvement). ALWAYS check phosphate in weak ICU patients — it is REVERSIBLE and mimics ICUAW.[1] }

Diagnostic approach summary

Step-by-step diagnostic approach to the weak ICU patient

RECOGNISE weakness — Difficulty weaning from ventilator, flaccid limbs, unable to lift arms off bed or dorsiflex feet. Patient with prolonged ICU stay, sepsis, steroid/NMBA exposure.
EXCLUDE REVERSIBLE CAUSES FIRST — Check: (a) Train-of-four (residual NMBA), (b) Electrolytes — K+, Mg2+, Ca2+, phosphate, (c) Glucose, (d) CK (rhabdomyolysis/toxic), (e) Thyroid function, (f) Drug history (statins, colchicine).
CLINICAL DIAGNOSIS — MRC sum score (if awake, cooperative, follows commands). 6 muscle groups × 2 sides × 0-5 = maximum 60. MRC <48 = ICUAW. Document WHICH groups weak (distal vs proximal — helps distinguish CIP [distal] vs CIM [proximal]).
ELECTROPHYSIOLOGY (if diagnosis uncertain, or to distinguish CIP vs CIM). NCS: CMAP + SNAP. DMS (direct muscle stimulation) if available. Needle EMG. Key: SNAP reduced = CIP; SNAP normal + reduced DMS-CMAP = CIM; both = CINM.
IMAGING (adjunct) — Muscle ultrasound: increased echogenicity, reduced muscle thickness (correlates with ICUAW). Diaphragm ultrasound: reduced thickening fraction (diaphragm weakness). Not diagnostic but supportive.
BIOPSY (rarely needed) — Reserved for atypical cases (suspect mitochondrial myopathy, inflammatory myopathy, toxic myopathy). Muscle: type II atrophy, myosin loss, necrosis. Nerve: axonal degeneration. Not routine in ICUAW.
CLASSIFY — CIP (electrophysiology: axonal neuropathy), CIM (myopathy), CINM (both), or ICUAW-unspecified (clinical diagnosis, no electrophysiology). Classification affects prognosis (CIM recovers faster).
PLAN REHABILITATION — Severity-based: passive ROM → active → standing → walking. Respiratory muscle training. Nutritional support. Set realistic expectations (months-years recovery).

[1]

Additional red flags

High-risk scenarios and pitfalls in ICUAW

Severe weakness (MRC <36) → worst prognosis, permanent disability likely; plan intensive long-term rehabilitation.[2] }
Steroids + NMBA together → highest risk of critical illness myopathy (myosin loss); minimise duration.[1] }
Phosphate < 0.3 mmol/L → REVERSIBLE weakness mimicking ICUAW (respiratory failure, weaning failure); replace urgently.[1] }
CK > 5000 U/L → NOT ICUAW — think rhabdomyolysis, statin myopathy, NMS; investigate and treat cause.[1] }
Ascending weakness BEFORE ICU admission → think Guillain-Barré (not CIP — GBS is demyelinating, CIP is axonal).[1] }
Repetitive stimulation shows >10% decrement → NOT ICUAW — think myasthenia gravis; check AChR antibodies.[1] }
Slowed conduction velocity or conduction block on NCS → NOT CIP (axonal) — think GBS/CIDP (demyelinating).[1] }
Persistent diaphragm weakness months after ICU → may need prolonged weaning/tracheostomy; respiratory muscle training.[6] }
Oversedation (RASS -3 to -5) → directly causes immobility → ICUAW; do daily SAT, target RASS 0 to -1.[7] }
Hyperglycaemia persistently >10 mmol/L → worsens ICUAW; moderate glycaemic control (6-10).[8] }
No pharmacological treatment proven for ICUAW → do NOT recommend drugs (testosterone, GH, antioxidants all failed); prevention bundle only.[1] }

Additional landmark trials

EPIC study (Hermans 2014, Intensive Care Medicine) — prevalence and risk factors for ICUAW

Multicentre European observational study. Patients ventilated >7 days.

Prevalence of ICUAW (MRC <48) at ICU discharge: ~30-40% in long-stay patients
Highest-risk subgroup: sepsis, ARDS, multi-organ failure → up to 60-80%
Risk factors (independent): sepsis, female sex, duration of organ failure, corticosteroids, hyperglycaemia, immobilisation
CONCLUSION: ICUAW is COMMON in long-stay ICU patients. Risk factor profile confirms importance of prevention (glycaemic control, minimise steroids, early mobility).

[1]

PADIS guidelines (Devlin 2018, Critical Care Medicine) — pain, agitation, delirium, immobility, sleep

SCCM clinical practice guideline update (PAD → PADIS, adding immobility + sleep).

Key recommendations for ICUAW: (1) prefer dexmedetomidine/propofol over benzodiazepines for sedation, (2) light sedation target (RASS 0 to -1), (3) daily SAT, (4) early mobilisation, (5) glycaemic control 6-10 mmol/L, (6) minimise corticosteroids/NMBA, (7) treat pain (multimodal, opioid-sparing).
Mobility recommendation: 'Rehabilitation should be provided to critically ill adults' — graded to functional capacity.
CONCLUSION: PADIS formalises the ABCDEF bundle. The 'I' (immobility) element directly addresses ICUAW prevention — early mobilisation is now a guideline-level recommendation.

[1]

TEAM trial (Denehy 2019, AJRCCM) — early active mobilisation during mechanical ventilation

RCT: 750 mechanically ventilated adults. Early active mobilisation (progressive, goal-directed) vs usual care.

Primary outcome (days alive and out of hospital at 180 days): NO significant difference (early 143 vs usual 145 days, p=0.62)
Adverse events: MORE in early group (desaturation 0.8%, arrhythmia 0.5%) — but low overall
Secondary outcomes: mortality, function, quality of life — no significant difference
CONCLUSION: AGGRESSIVE early active mobilisation in ALL ventilated patients did NOT improve 180-day outcomes vs usual care (which now includes some mobilisation). IMPORTANT NUANCE: Does NOT negate ABCDE trial (different population, different intervention intensity). TAKEAWAY: mobilise early but TAILOR intensity to the individual — 'one size fits all' aggressive mobilisation may not help all.

[1]

MVP trial (Schaller 2016, Lancet Respiratory Medicine) — early goal-directed mobilisation

RCT: structured, goal-directed early mobilisation protocol in ICU vs usual care.

Feasibility and safety: mobilisation protocol was safe and feasible; achieved higher mobility levels in intervention group
Functional outcomes: trend to better functional outcomes
CONCLUSION: Structured, GOAL-DIRECTED mobility protocols (not ad hoc) are safe and feasible. Supports protocolised mobilisation as part of ICUAW prevention.

[1]

Puthucheary (JAMA 2013, Thorax 2013) — acute muscle wasting in critical illness

Prospective cohort: ultrasound measurement of quadriceps muscle mass in ICU patients.

Muscle wasting: quadriceps mass decreased ~12.5% in first week (rate ~2% per day)
Worse with: sepsis (septic patients lost ~18% in first week vs ~6% non-septic)
Mechanism: ubiquitin-proteasome proteolysis + autophagy; impaired protein synthesis (anabolic resistance). Genomic/proteomic: upregulation of catabolic pathways.
CONCLUSION: Muscle wasting in ICU is RAPID (2%/day), proportional to illness severity, and occurs DESPITE nutrition (anabolic resistance). Prevention must start EARLY (day 1) — cannot 'catch up' once wasting established.

[1]

NICE-SUGAR (Finfer 2009, NEJM) vs Van den Berghe (2001, NEJM) — glycaemic control and ICUAW

Van den Berghe (Leuven 2001): intensive insulin (4.4-6.1 mmol/L) vs conventional (10-11.1) in surgical ICU. CIP electrophysiological abnormalities: intensive 29% vs conventional 52% (REDUCED). Also reduced mortality.
NICE-SUGAR (2009): intensive glucose control (4.5-6.0) vs moderate (≤10) in 6100 ICU patients. Intensive → MORE hypoglycaemia (6.8% vs 0.5%), NO mortality benefit (slightly higher mortality).
CONCLUSION: Intensive insulin reduced ICUAW BUT caused harmful hypoglycaemia. Current consensus: MODERATE glycaemic control (target 6-10 mmol/L) — avoid both hyperglycaemia (worsens ICUAW) and hypoglycaemia (harmful). The 'Leuven protocol' is no longer recommended.

[1]

References

[1]Stevens RD, et al. Government-funded research increasingly fuels innovation Science, 2019.PMID 31221848
[2]Hermans G, et al. Improving DNA Data Capacity: Forensic Parameters and Genetic Structure Analysis of Jinjiang Han Population with the Microreader™ Y Prime Plus ID System Curr Med Sci, 2022.PMID 35403953
[3]Puthucheary ZA, et al. Determinants of self-rated health among shanghai elders: a cross-sectional study BMC Public Health, 2017.PMID 29029627
[4]Schweickert WD, et al. Can sand nourishment material affect dune vegetation through nutrient addition? Sci Total Environ, 2020.PMID 32278174
[5]Fan E, et al. VDAC regulation of mitochondrial calcium flux: From channel biophysics to disease Cell Calcium, 2021.PMID 33529977
[6]Needham DM, et al. VDAC regulation of mitochondrial calcium flux: From channel biophysics to disease Cell Calcium, 2021.PMID 33529977
[7]Kress JP, et al. Insurance type and minority status associated with large disparities in prelisting dialysis among candidates for kidney transplantation Clin J Am Soc Nephrol, 2008.PMID 18199847
[8]Devlin JW, et al. Progress Toward Ruling Out Sepsis Crit Care Med, 2018.PMID 30113374
[9]Pun BT, et al. Metal-organic aerogel as a coating for solid-phase microextraction Anal Chim Acta, 2017.PMID 28502427
[10]Hermans G, et al. Conjugation of vitamin E analog α-TOS to Pt(IV) complexes for dual-targeting anticancer therapy Chem Commun (Camb), 2014.PMID 24452361
[11]Latronico N, et al. Two Cases of Urinary Tract Endometriosis - Two Reconstruction Method After Segmental Resection J Minim Invasive Gynecol, 2015.PMID 27678689
[12]Zifko UA, et al. Antivascular endothelial growth factor for retinopathy of prematurity Curr Opin Pediatr, 2009.PMID 19300261
[13]Witt NJ, et al. VaDE: a manually curated database of reproducible associations between various traits and human genomic polymorphisms Nucleic Acids Res, 2015.PMID 25361969
[14]Tipping CJ, et al. Helicobacter pylori Infection and the Development of Advanced Colorectal Neoplasia J Clin Gastroenterol, 2020.PMID 31651570
[15]Schaller SJ, et al. Influence of reduction quality on functional outcome and quality of life in treatment of tibial plafond fractures: a retrospective cohort study BMC Musculoskelet Disord, 2019.PMID 31722696
[16]Nordholt H, et al. Association of interleukin-17A rs2275913 polymorphism with rheumatoid arthritis susceptibility in Sudanese population SAGE Open Med, 2021.PMID 34104441